Olaparib in the Treatment of BRCA1/2 Unmutated and BRCA1 Promoter Methylated Recurrent and Metastatic Triple-negative Breast Cancer

Sponsor
Hebei Medical University Fourth Hospital
Study ID
NCT05522491
Phase
PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Solid Tumor

Eligibility Criteria

Sex
FEMALE
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • Olaparib — DRUG
    All subjects enrolled will receive olaparib.Subjects continued to take medication until disease progression, unacceptable toxicity, withdrawal of informed consent, or discontinuation of medication at the discretion of the investigator.

Study Details

This is an open-label, single-arm, single-center,exploratory clinical study.

Key Dates

Start date
Sep 1, 2026
Status verified
Aug 2025
Primary completion
Sep 1, 2030
Completion
Sep 1, 2031

Study Design

Enrollment
30 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Olapalib
    Olaparib Oral 300mg 2/day; 4 weeks (28 days) as a treatment cycle.

Primary Outcome Measure

ORR ORR [ Time Frame: 24 month ]

Related Studies